leadf
logo-loader
viewOpen Orphan PLC

Venn Life Sciences eyes first acquisition target after £4.5mln raise

Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of Open Orphan, speaks to Proactive London's Andrew Scott after successfully raising £4.5mln in a share placing.

Friel is reversing Open Orphan into Venn in a £5.7mln all-paper deal to bring to the market his platform that helps pharma companies commercialise their products in Europe.

Friel and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

Quick facts: Open Orphan PLC

Price: 18.499 GBX

AIM:ORPH
Market: AIM
Market Cap: £123.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

on 08/10/2020

2 min read